Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III non-inferiority trial of JMT103 versus denosumab in giant cell tumor of bone
CTR20231025Phase 3Active
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of narlumosbart in Giant Cell Tumor of Bone (GCTB), sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Started Sep 2023; status: active.
02
Drugs
narlumosbart
03
Conditions
Giant Cell Tumor of Bone (GCTB)
Beyond the preview
Go deeper on CTR20231025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231025.